Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2023 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
November 02, 2023 09:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2...
October 14, 2023 12:30 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and...
August 08, 2023 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023 Enrollment for Phase 3 PEAK trial in GIST continues on...
June 09, 2023 16:01 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
June 07, 2023 09:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., June 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
June 06, 2023 20:25 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
June 06, 2023 16:05 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
June 03, 2023 14:15 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable...
May 23, 2023 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

WALTHAM, Mass. and BOULDER, Colo., May 23, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...